ACIU Stock — AC Immune Ltd

AC Immune Ltd (ACIU)

Updated October 16, 2026.

ACIU is a Stock. Total return is -84.7% over the past 10.1 years, 398.5 points behind SPY at 313.8%.

AC Immune is a clinical-stage biopharmaceutical company developing medicines and diagnostic products for neurodegenerative diseases caused by protein misfolding, including Alzheimer's disease, Parkinson's disease, and related conditions. The company uses its SupraAntigen and Morphomer platforms to create biologics and small molecules targeting misfolded proteins, with lead programs including monoclonal antibodies and diagnostic imaging agents developed through partnerships with major pharmaceutical companies including Genentech, Janssen, and Eli Lilly. As an early-stage biotech company, it does not currently distribute to shareholders and operates on clinical development timelines typical of the sector.

ACIU performance versus SPY

Price and return data through 2026-10-16.

Total return is -84.7% over the past 10.1 years, 398.5 points behind SPY at 313.8%. Over the past year its total return — price change plus distributions reinvested — is -19.3%. Its deepest 1-year drawdown was 44.8%.

ACIU key facts

Asset type

Stock

Asset class

Equity

Inception date

09/23/2016

Distribution frequency

None

Last close

$2.39 (as of 2026-10-16)

Market cap

$237,630,367

Average volume

126849.0

Beta

1.553

Payout ratio

0.0%

Forward P/E

16.6389

EPS

$-0.54

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ACIU risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 44.8%.

Who may consider ACIU — and who may not

It is a weaker fit for investors who need monthly cash flow (ACIU does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ACIU

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions